RxDoctor Payments Data

Grant Jaspers

Family · Sioux Falls, SDNPI 1457723660

Payments from drug & device makers

$1,372in general payments, 2019–2025

Across 71 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$154
  • Bristol Myers Squibb$149
  • Geron Corporation$144
  • AstraZeneca$90
  • AbbVie$84
  • Gilead$83
  • plus $668 from 17 others

What the payments were for

  • Food & beverage$1,372100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,372 in reported general payments places this provider in the 80th percentile of 588 family providers in South Dakota.

See all family providers in South Dakota

Medicare billing

Part B allowed, 2024
$39,749
Medicare patients
189
Services billed
777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide62$1,144,528
JakafiRuxolitinib Phosphate12$184,410
VenclextaVenetoclax17$57,067
EliquisApixaban21$19,213
ValacyclovirValacyclovir Hcl32$2,842
Acyclovir173$1,279
Fluconazole22$1,095
Hydroxyurea46$731
Dexamethasone46$617
Ondansetron OdtOndansetron31$441
Levofloxacin20$278
Potassium Chloride21$232
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim32$171
Gabapentin16$132
Pantoprazole Sodium15$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$149$1,144,52862 claims
Incyte CorporationJakafi$39$184,41012 claims
AbbVieVenclexta$84$57,06717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 588 family providers in South Dakota.

Other family in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →